Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-IL-3R alpha/CD123 Antibody (3M211) is a Rabbit antibody targeting IL-3R alpha/CD123. Anti-IL-3R alpha/CD123 Antibody (3M211) can be used in WB,ELISA,IP.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 μL | $268 | 7-10 days |
Description | Anti-IL-3R alpha/CD123 Antibody (3M211) is a Rabbit antibody targeting IL-3R alpha/CD123. Anti-IL-3R alpha/CD123 Antibody (3M211) can be used in WB,ELISA,IP. |
Alias | interleukin 3 receptor, α (low affinity), interleukin 3 receptor, alpha (low affinity), IL3RY, IL3RX, IL3RAY, IL-3R α/CD123, IL3R, hIL-3Ra, CD123 |
Ig Type | Monoclonal Rabbit IgG |
Clone | 3M211 |
Reactivity | Human |
Verified Activity | 1. Anti-IL3RA rabbit monoclonal antibody at 1:500 dilution. -Lane A: Hela Whole Cell lysate. -Lysates/proteins at 30 μg per lane. -Secondary -Goat Anti-Rabbit IgG H&L (Dylight800) at 1/10000 dilution. -Developed using the Odyssey technique. -Performed under reducing conditions. -Predicted band size:43 kDa. -Observed band size:38 kDa. 2. IL3RA was immunoprecipitated using: -Lane A:0.5 mg Hela Whole Cell Lysate. -Lane B:0.5 mg MCF-7 Whole Cell Lysate -0.5 µL anti-IL3RA rabbit monoclonal antibody and 15 μl of 50 % Protein G agarose. -Primary antibody: -Anti-IL3RA rabbit monoclonal antibody, at 1:350 dilution. -Secondary antibody: -Dylight 800-labeled antibody to rabbit IgG (H+L), at 1:5000 dilution. -Developed using the odyssey technique. -Performed under reducing conditions. -Predicted band size: 43 kDa. -Observed band size: 38 kDa |
Application | WB,ELISA,IP |
Recommended Dose | WB: 1:500-1:1000; ELISA: 1:25000-1:50000; IP: 0.2-1 μL/mg of lysate |
Antibody Type | Monoclonal |
Host Species | Rabbit |
Construction | This antibody was obtained from a rabbit immunized with purified, recombinant Human IL3RA / CD123 (rh L3RA; TMPY-01410; NP_002174.1; Met 1-Arg 305). |
Purification | Protein A |
Appearance | Liquid |
Formulation | 0.2 μm filtered solution in PBS |
Research Background | Interleukin-3 receptor subunit alpha, also known as IL-3 receptor subunit alpha, IL-3R-alpha, CD123, and IL3RA, is a single-pass type I membrane protein that belongs to the type I cytokine receptor family and Type 5 subfamily. The specific alpha subunit of the interleukin-3 receptor (IL-3Ralpha, CD123) is strongly expressed in various leukemic blasts and leukemic stem cells and seems to be an excellent target for the therapy of leukemias. The WSXWS motif of IL3RA appears to be necessary for proper protein folding and thereby efficient intracellular transport and cell-surface receptor binding. The box one motif of IL3RA is required for JAK interaction and/or activation. IL3RA represents a unique marker for primitive leukemic stem cells. Targeting of IL3RA may be a promising strategy for the preferential ablation of AML cells. Aberrant IL3RA expression is a good marker for monitoring of minimal residual disease. IL3RA is strongly expressed in various leukemic blasts and leukemic stem cells and seems to be an excellent target for the therapy of leukemias. Recent studies have shown that interleukin-3 receptor alpha (CD123) is highly expressed on leukemia stem cells of patients with acute myeloid leukemia, and is correlated with tumor load and poor prognosis. CD123 was highly expressed in the bone marrow of the patients with myelodysplastic syndrome (MDS), significantly correlated with the proportion of bone marrow blasts, and thus might be the marker of MDS malignant clone. IL3RA is also a useful new marker for distinguishing B-cell disorders with circulating villous lymphocytes as its expression is characteristic of typical hairy cell leukemia (HCL) with high sensitivity and specificity. |
Conjucates | Unconjugated |
Immunogen | Recombinant Human IL3RA protein (TMPY-01410) |
Antigen Species | Human |
Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.